I nostri team di ricerca e sviluppo sono distribuiti in tutto il mondo, generando sinergie grazie alle nostre competenze specializzate e discipline correlate. Partecipiamo a uno scambio internazionale con istituzioni specializzate indipendenti, opinion leader e moltiplicatori chiave, al fine di garantire la cooperazione e la gestione delle conoscenze ai massimi livelli. Come parte di questo impegno, conduciamo ricerche approfondite che vengono continuamente presentate ai congressi sotto forma di poster o conferenze dai nostri partner di cooperazione, nonché ai simposi e workshop, e pubblicati su riviste scientifiche rinomate. Le pubblicazioni specialistiche basate sulle evidenze, per lo più valutate da revisori indipendenti, sono disponibili in questo database:
-
Journal article
Efficacy of a Ready-Made Tubular Compression Device Versus Short-Stretch Compression Bandages in the Treatment of Venous Leg Ulc
Wounds 2004 16(10) 313320Products Rosidal K -
Journal article
A hydrogel that may help relieve sunburn pain
Practice Nursing 2004 15(11) 565567Downloads Citation (RIS) -
Journal article
Development and testing of a novel biosynthesized XCell for treating chronic wounds
Surgical technology international 2004 12 2733Biosynthesized cellulose is produced by the bacteria, Acetobacter xylinum, and possesses unique properties not present in other biomaterials. The material is formed during fermentation having a multi-layered structure composed of fine, nonwoven, cellulose hydrophilic fibers. This structure allows biosynthesized cellulose to have a high-fluid capacity, superior strength, and biocompatibility, which makes it suitable for topical and implantable biomedical applications. Initial product development of biosynthesized cellulose has focused on advanced wound-care applications. The product, XCell (Xylos Corporation, Langhorne, PA, USA), has been bioengineered to have the ability to both donate and absorb moisture, depending on the wound environment. Comparative bench testing has shown that XCell is the only wound dressing with this unique dual-fluid-handling capability. The product has been studied thoroughly using animal models and proved to be safe and biocompatible. Human clinical testing has demonstrated its effectiveness in providing a moist environment, essential to treating hard-to-heal chronic wounds. The major clinical benefits of the product include: 1) help in removal of non-viable tissue and promotion of autolytic debridement, which results in increased granulation tissue; 2) cleansing of wound margins that leads to epithelial migration and reduction of wound size; and 3) healing of various types of chronic wounds.
Products Suprasorb XPMID 15455308Downloads Citation (RIS) -
Poster
Das antioxidative Potential von Suprasorb® C – positiver Einfluß bei chronisch-stagnierenden Wunden
Poster presented at DGfW 2003 26.06.2003 Augsburg, GermanyProducts Suprasorb C -
Poster
Randomised Trial Comparing Four Layer with Actico Cohesive Short Stretch Compression Bandaging in the Management of Chronic Venous Ulceration
Poster presented at Tissue Viability Nurse Conference 2003 08.04.2003 Blackpool, UKFurther versions -
Journal article
Chronisch-stagnierende Wunden: Aus der Flaute - volle Fahrt in Richtung Heilungserfolg
ZfW 2003 148152Products Suprasorb C, Suprasorb PDownloads Citation (RIS) -
Journal article
Practical issues in the management of superficial pre-tibial skin tears in the older person
Nurse2Nurse Magazine 2003 3(3) 42Downloads Citation (RIS) -
Journal article
Short stretch bandaging: a case history
Nurse2Nurse Magazine 2003 3(3) 4344Downloads Citation (RIS) -
Poster
METHODS OF TREATMENT IN MODERN WOUND MANAGEMENT EXAMPLIFIED AT ULCUS CRURIS
Poster presented at EWMA 2002 23.05.2002 Granada, Spain -
Poster
MANAGEMENT OF THE DIABETIC FOOT
Poster presented at EWMA 2002 23.05.2002 Granada, Spain